Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Serabi delivers 'strong start' as Q1 profits jump

(Sharecast News) - Gold miner Serabi delivered a "strong start" to 2025, with output, prices and profits rising strongly compared with last year, with the board encouraged by recent drilling activity. Gold production totalled 10,013 ounces over the first three months of the year, up from 9,007 ounces mined in the same period the year before.

Growth was driven by higher feed grades at both Palito and Coringa, supported by the first full quarter of operations at the Coringa classification plant.

This contributed to cash generation of $4.2m for the quarter, increasing the cash position to $26.5m by 31 March, up from $22.2m three months earlier.

Meanwhile, the average realised gold price jumped to $2,908 per ounce, compared with the average $2,407 price for 2024 as a whole.

EBITDA totalled $12.4m for the quarter, jumping from $4.7m previously.

"Q1 2025 marked a strong start to the year, continuing the positive momentum from H2-2024," said chief financial officer colm Howlin.

"We also commenced our 2025 exploration programme, with $9m allocated for the year and a similar commitment anticipated for 2026. Drilling activity is now underway at both Palito and Coringa. Early drill results from the programme have been encouraging. We look forward to providing an exploration update in the oncoming weeks."

Serabi shares were down 0.8% at 151.32p by 0922 BST, having surged by more than a third so far this year.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.